Abstract: A therapy system in which one or more eye patches are used to apply thermal energy to meibomian glands of an eye of a user to improve the release of meibum. The system comprises includes a headband which is worn by a user and in which a control unit is provided. At least one eye patch is provided which is connectable to the control unit. Each eye patch includes an outer area, an inner area with a flexible heating element located in the inner area. Electrical connections are used to connect the flexible heating element to the control unit to provide at least heat therapy to at least the meibomian gland in the eyelids. A charging unit is provided for recharging a rechargeable battery in the control unit.

Abstract: This invention provides for a dermal repair system including a dermal repair device which is configured to be placed on the skin of a user. The dermal repair device is in the form of a removable silicone sheet which can be securely fixed in place and re-used after cleaning etc. The silicone sheet includes sheet sections and a housing section into which a rechargeable control unit can removably be inserted. Waveguides in the form of a dimple teardrop pattern are provided for directing radiation or light to distal ends of the sheet. The control unit includes a low-level radiation or light source from which radiation or light is directed along the sheet for a therapy regimen to treat closed wounds and scars, such as, C-section and breast surgery closed wounds and scars to improve healing and scar appearance. The system further comprises a recharging station configured for recharging the control unit.

Abstract: Ocular devices are provided for placement in the upper fornix of the eye and having a body that encompasses a low-level light source, an energy source, a microcontroller, and an antenna for delivering a programmable, fade in-out, light therapy regimen to treat neurological and ophthalmic diseases and disorders. In one embodiment the ocular device delivers a programmable green light therapy to reduce elevated intraocular pressure (IOP) and retinal hypoxia during the nocturnal period, that is, when these risk factors are at their highest level especially in glaucoma, age-related macular degeneration and diabetic retinopathy patients.